OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Siu on the Rationale for Combining Petosemtamab With Pembrolizumab in HNSCC

October 4th 2024

Lillian L. Siu, MD, FRCPC, discusses the background for evaluating first-line petosemtamab plus pembrolizumab in recurrent/metastatic PD-L1+ HNSCC.

Dr Machaalani on the Incidence of ERBB2 Amplifications Across Race, Sex, and Cancer Type

October 4th 2024

Marc Machaalani, MD, discusses an investigation into the distribution of ERBB2 amplifications across sex, race, and varying cancer types.

Dr Awad on the FDA Approval of Perioperative Nivolumab for Resectable NSCLC

October 3rd 2024

Mark Awad, MD, PhD, discusses the significance of the FDA approval of perioperative nivolumab for patients with resectable NSCLC.

Dr Cosman on the Potential Utility of MT-302 in TROP-2–Expressing Epithelial Cancers

October 3rd 2024

Rasha Cosman, BSc, MBBS, FRACP, discusses the mechanism of action and potential role for the in vivo mRNA CAR therapy MT-302 in TROP-2–expressing epithelial cancers.

Dr Usmani on Challenges With Bispecifics and CAR T-Cell Therapies in Multiple Myeloma

October 3rd 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses challenges of integrating bispecific antibodies and CAR T-cell therapies into the community for myeloma.

Dr McAndrew on a Subgroup Analysis of NATALEE in HR+/HER2– Early Breast Cancer

October 3rd 2024

Nicholas P. McAndrew, MD, MSCE, discusses a subgroup analysis of the NATALEE trial in HR+/HER2– early breast cancer by prior systemic treatment.

Dr Hu on the Evaluation of Tibremciclib Plus Fulvestrant in HR+/HER2– Advanced Breast Cancer

October 3rd 2024

Xichun Hu, MD, PhD, discusses a study of tibremciclib plus fulvestrant in HR+/HER2– advanced breast cancer following progression on endocrine therapy.

Dr Girard on PROs From the LUMINOSITY Trial in c-Met–Overexpressing NSCLC

October 3rd 2024

Nicolas Girard, MD, discusses PROs from the LUMINOSITY trial of Teliso-V in patients with c-Met protein–overexpressing, EGFR wild-type, nonsquamous NSCLC.

Dr Dhakal on Survival and Safety Outcomes With Cilta-Cel in R/R Myeloma

October 2nd 2024

Binod Dhakal, MD, discusses survival data with ciltacabtagene autoleucel in lenalidomide-refractory relapsed/refractory multiple myeloma.

Dr Corre on MRD Negativity With D-VTd Induction/Consolidation in Newly Diagnosed Multiple Myeloma

October 2nd 2024

Jill Corre, PharmD, PhD, discusses minimal residual disease negativity rates after treatment with D-VTd induction/consolidation in newly diagnosed multiple myeloma.

Dr Usmani on the Efficacy of Daratumumab Plus VRd in Newly Diagnosed, Transplant-Ineligible Myeloma

October 1st 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the efficacy of daratumumab plus VRd in patients with transplant-ineligible or -deferred multiple myeloma.

Dr Badros on the Efficacy of Daratumumab Plus Lenalidomide in Newly Diagnosed Myeloma

October 1st 2024

Ashraf Badros, MBCHB, discusses the addition of subcutaneous daratumumab to lenalidomide vs lenalidomide alone in newly diagnosed myeloma following ASCT.

Dr George on Other Potential Roles for Radioligand Therapy in Prostate Cancer

September 30th 2024

Daniel J. George, MD, discusses the potential use of lutetium-177 earlier in the treatment paradigm for metastatic castration-resistant prostate cancer.

Dr Siu on the Investigation of Petosemtamab Plus Pembrolizumab in PD-L1+ HNSCC

September 30th 2024

Lillian L Siu, MD, FRCPC, discusses a phase 3 trial of petosemtamab plus pembrolizumab vs pembrolizumab alone for recurrent/metastatic PD-L1+ HNSCC.

Dr Eng on Unmet Needs Within the mCRC Treatment Paradigm

September 30th 2024

Cathy Eng, MD, FACP, FASCO, discusses unmet needs within the metastatic colorectal cancer treatment paradigm.

Dr Ng on Factors That Influence Later-Line Treatment Decisions in mCRC

September 30th 2024

Kimmie Ng, MD, MPH, discusses factors of consideration for later-line treatment decisions in patients with refractory metastatic colorectal cancer.

Dr Koff on Frontine and Maintenance Treatment Decision-Making in MCL

September 27th 2024

Jean L. Koff, MD, MS, discusses factors that influence treatment decision-making for patients with MCL in the frontline and maintenance settings.

Dr Battiwalla on the Expanding Use of Bispecific Antibodies in NHL

September 27th 2024

Minoo Battiwalla, MD, MS, discusses the variety of bispecific antibodies evaluated for patients with NHL, including DLBCL.

Dr Gluz on Survival Outcomes With De-Escalated Neoadjuvant Regimens in HR+/HER2+ Early Breast Cancerer

September 27th 2024

Oleg Gluz, MD, discusses data from the WSG-TP-II trial of neoadjuvant endocrine therapy plus trastuzumab and pertuzumab in HR+/HER2+ early breast cancer.

Dr Necchi on Responses With TAR-200 According to PD-L1 Status in NMIBC

September 27th 2024

Andrea Necchi, MD, discusses treatment with TAR-200 by PD-L1 expression in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer with CIS.